阿米万他单抗治疗EGFR突变非小细胞肺癌的真实世界疗效与安全性
本研究为多中心真实世界分析,纳入61例接受阿米万他单抗治疗的EGFR突变非小细胞肺癌患者。总体可评估54例中19例(45.2%)出现临床缓解,疾病控制率为64.3%。作者认为,阿米万他单抗对20号外显子插入突变以外的EGFR突变可能是有效治疗选择,与奥希替尼联合安全可行。
要点
- 总体可评估54例中19例(45.2%)出现临床缓解,疾病控制率为64.3%。
- 非典型突变队列7例中6例(85.7%)出现临床缓解,疾病控制率为100%。
- 与放疗联合(同期或序贯)未见额外毒性。
核心结论
- 作者认为,真实世界多中心分析显示,阿米万他单抗对20号外显子插入突变以外的EGFR突变患者可能是有效的治疗选择。
- 作者认为,阿米万他单抗与奥希替尼联合安全可行。
- 作者认为,放疗与阿米万他单抗序贯或同期给药似乎也是安全的。
研究设计与样本
- 研究为真实世界多中心分析,数据来自MD Anderson肺癌GEMINI、Fred Hutchinson癌症研究中心、加州大学戴维斯综合癌症中心和斯坦福癌症中心的数据库。
- 纳入的是未参加临床试验、接受阿米万他单抗治疗的EGFR突变非小细胞肺癌患者,共61例。
- 患者中位年龄为65(31-81)岁,72.1%为女性,77%为从不吸烟者。
- 既往治疗线数中位数为四线。
- 按肿瘤EGFR突变分组:经典突变组39例、20号外显子插入突变组15例、非典型突变组7例。
主要发现
- 37例(58.7%)患者同时接受奥希替尼治疗,25例(39.1%)患者同时接受放疗。
- 总体人群中54例可评估缓解,19例(45.2%)出现临床缓解,疾病控制率为64.3%。
- 经典突变组33例可评估患者中12例(36.4%)出现临床缓解,疾病控制率为48.5%。
- 非典型突变组7例中6例(85.7%)出现临床缓解,疾病控制率为100%。
- 20号外显子插入突变组13例可评估患者中5例(35.7%)出现临床缓解,疾病控制率为64.3%。
临床怎么用
- 作者认为,阿米万他单抗对20号外显子插入突变以外的EGFR突变患者可能是有效的治疗选择。
- 作者认为,奥希替尼与阿米万他单抗联合安全可行。
- 作者认为,放疗与阿米万他单抗序贯或同期给药似乎也是安全的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Amivantamab-vmjw (amivantamab) is a bispecific EGFR/MET antibody approved for patients with advanced NSCLC with EGFR exon 20 insertion mutations, after prior therapy. Nevertheless, the benefits and safety of amivantamab in other EGFR-mutant lung cancer, with or without osimertinib, and with concurrent radiation therapy, are less known. METHODS: We queried the MD Anderson Lung Cancer GEMINI, Fred Hutchinson Cancer Research Center, University of California Davis Comprehensive Cancer Center, and Stanford Cancer Center's database for patients with EGFR-mutant NSCLC treated with amivantamab, not on a clinical trial. The data analyzed included initial response, duration of treatment, and concomitant radiation safety in overall population and prespecified subgroups. RESULTS: A total of 61 patients received amivantamab. Median age was 65 (31-81) years old; 72.1% were female; and 77% were patients with never smoking history. Median number of prior lines of therapies was four. On the basis of tumor's EGFR mutation, 39 patients were in the classical mutation cohort, 15 patients in the exon 20 cohort, and seven patients in the atypical cohort. There were 37 patients (58.7%) who received amivantamab concomitantly with osimertinib and 25 patients (39.1%) who received concomitant radiation. Furthermore, 54 patients were assessable for response in the overall population; 19 patients (45.2%) had clinical response and disease control rate (DCR) was 64.3%. In the classical mutation cohort of the 33 assessable patients, 12 (36.4%) had clinical response and DCR was 48.5%. In the atypical mutation cohort, six of the seven patients (85.7%) had clinical response and DCR was 100%. Of the 13 assessable patients in the exon 20 cohort, five patients (35.7%) had clinical response and DCR was 64.3%. Adverse events reported with amivantamab use were similar as previously described in product labeling. No additional toxicities were noted when amivantamab was given with radiation with or without osimertinib. CONCLUSIONS: Our real-world multicenter analysis revealed that amivantamab is a potentially effective treatment option for patients with EGFR mutations outside of exon 20 insertion mutations. The combination of osimertinib with amivantamab is safe and feasible. Radiation therapy also seems safe when administered sequentially or concurrently with amivantamab.
引用
- Wang K, Du R, Myall NJ, et al. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2023. PMID: 38012986. doi:10.1016/j.jtho.2023.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。